A multicentre, randomised placebo controlled, parallel group clinical trial to evaluate the anti-neoplastic effects of Taurolidine in patients undergoing curative surgery for non-metastatic colon cancer.
Latest Information Update: 08 Jan 2018
Price :
$35 *
At a glance
- Drugs Taurolidine (Primary)
- Indications Colon cancer
- Focus Pharmacodynamics
- Sponsors Geistlich
- 06 Jan 2018 Status changed from recruiting to completed.
- 01 Aug 2011 New trial record